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Reportedly, it was Hippocrates (ca. 460–370 BC) and 
Galenos (Galen of Pergamum; ca AD 129–199) who first 
stated that a poison, and not evil spirits, must be respon-
sible for symptoms such as fever, vomiting and diar-
rhea [1]. Naturally, the nature of this ‘poison’ remained 
unclear. Richard Pfeiffer (1858–1945) discovered that 
a toxic substance was associated with the membrane of 
bacteria, and called it ‘endotoxin’ [2]. Endotoxin infusion 
mimics many of the inflammatory, metabolic, cardiovas-
cular changes observed in sepsis patients and represents 
one of the main inducers of shock in sepsis. The discov-
erer of its receptor (the Toll-like receptor 4) [3], Nüsslein-
Volhard was awarded the Nobel prize for this discovery 
in 1995, further propelling this field of research.
Clinical research has shown that endotoxin is indeed 
circulating in the blood of up to 50% of sepsis shock 
patients [4] and associated with impaired clinical out-
come [5]. In view of the pivotal role of endotoxin in 
sepsis patients, the idea of ‘blood purification’ emerged. 
Polysterene fiber filters coated with polymyxin B are able 
to bind endotoxin (Fig. 1). A meta-analysis of trials pri-
marily of Japanese origin indicated a survival benefit for 
patients treated with polymyxin B hemoperfusion [6]. 
Since then, two randomized trials from Europe and one 
from USA/Canada have been conducted.
In 2009, the Euphas-trial (Early Use of Polymyxin B 
Hemoperfusion in Abdominal Septic shock), an open-
label randomized study performed in Italy, was published 
[7]. Sixty-four patients with abdominal severe sepsis 
or septic shock were treated with PMX hemoperfusion 
(or standard of care) within 6  h following surgery. The 
primary end-point of this study was the change (from 
day 0 to 3) in hemodynamic stability. Secondary end-
points included change in SOFA-score and mortality. 
The authors reported an improvement in hemodynamic 
stability in the PMX hemoperfusion group, while this 
was not the case in the control group. In addition, sur-
vival time analysis showed a significant improvement in 
the treatment group. The trial was stopped prematurely 
based on these results. A discussion emerged [8], as it 
was highlighted that no significant differences between 
the 2 groups were present, and that polymyxine B 
hemoperfusion appears to prolong time to mortality, but 
did not significantly affect day 28 mortality. Early termi-
nation of the study was deemed unfortunate [8].
Six years later, the Abdomix-trial from France was pub-
lished [9]. Again, abdominal septic shock patients were 
randomized to PMX-hemoperfusion treatment (n = 119) 
or to the control group (n = 113). The first hemoperfu-
sion session started within 12  h following surgery and 
was repeated 24  h later. Adequacy of surgical proce-
dure was blindly evaluated by an independent surgeon 
and classified as adequate, sufficient, or inadequate. The 
28-day mortality was 28% in the PMX-group versus 20% 
in the control group (p = 0.1). Incomplete PMX sessions 
occurred in 11% of the patients due to circuit coagula-
tion mainly during the 1st session. Importantly, also in 
the subgroup having received adequate surgery and two 
uneventful complete PMX sessions, no sign of a ben-
eficial effect of treatment was observed. Finally, neither a 
more rapid improvement in SOFA-score in the treatment 
group nor a more rapid decrease in circulating cytokines 
was found in this study [10]. Potential reasons for these 
findings were discussed [11, 12].
In the recently finalized Euphrates trial [13] (Evaluating 
the Use of Polymyxin B Hemoperfusion in a Randomized 
controlled trial of Adults Treated for Endotoxemia 
and Septic shock), PMX hemoperfusion was applied 
in a blinded manner in patients with septic shock and 
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confirmed endotoxemia, as measured by the endotoxin 
activity assay (EAA). The trial, conducted in the United 
States and Canada, was powered to enroll 360 patients to 
detect an effect on 28-day all-cause mortality. Similar to 
the previous trials, treatment consisted of two sessions 
of PMX hemoperfusion 24  h apart. Unique features of 
this trial included patient enrichment by use of EAA to 
confirm endotoxemia (EAA > 0.6) and use of a detailed 
“façade” hemoperfusion event as a blinding mecha-
nism. Following the second interim analysis, the study 
was resized to 650 patients. However, after 446 evalu-
able patients were included, the trial was terminated. 
The study has not yet been published, but Spectral, the 
company of the EAA, has stated that it failed to meet its 
primary end-point. There was a non-significant 5% mor-
tality reduction in the per protocol population, and it is 
mentioned that ‘other positive benefits were observed’ in 
treated septic shock patients compared to standard treat-
ment [14]. Currently, no further details have been made 
public and it remains unclear to what extent timing of the 
intervention and the amount of endotoxin adsorped by 
the membrane may play a role.
New developments are emerging. Coupled plasma 
filtration adsorption is another extracorporeal blood 
purification therapy for sepsis which adsorbs both pro-
inflammatory and anti-inflammatory mediators from 
filtered plasma. Effects on clinical outcome are awaited. 
The ‘Cytosorb’-filter, with polymer beads that have pores 
that can adsorb hydrophobic molecules in a size range 
of approximately 10–55 kD (sufficient to remove almost 
all known cytokines, including HMGB-1, but not endo-
toxin), has a huge absorption area of 40,000  m2, and 
several case series have been published. Unfortunately, 
in a small (n =  37 patients) blinded, randomized study 
in cardiac surgery patients, installment of the adsorber 
on the cardio-pulmonary bypass machine had no effect 
on surgery-induced cytokine release or hemodynamic 
stability measures [15]. The ‘oXiris’-filter is designed to 
adsorb endotoxin as well as cytokines, but no adequately 
powered human study is currently available.
While removal of endotoxin/cyokines is theoretically 
seen as a beneficial effect, other potentially detrimen-
tal effects may also occur. As both pro-and anti-inflam-
matory cytokines may decrease, the net effect is 
uncertain. In addition, other nutrients and therapeutic 
drugs (including antibiotics) may also be removed from 
the circulation, with potential negative impact on organ 
function and recovery.
The high incidence and morbidity, mortality, and asso-
ciated costs of septic shock illustrate that the medical 
need for an adjuvant treatment is still unmet. Endotoxin, 
one of the most potent mediators of sepsis, is found in 
high levels in approximately half of patients with sep-
tic shock. Polymyxin B (PMX) hemoperfusion has been 
shown in numerous studies to successfully remove 
endotoxin and potentially improve outcomes. Although 
numerous case series and small studies suggest that these 
beneficial effects may also be present in sepsis patients, 
larger randomized controlled trials have not confirmed 
these findings. While blood purification in sepsis is a 
valid approach, the potential efficacy of LPS/cytokine 
elimination using these membranes currently cannot be 
estimated without positive clinical data from randomized 
trials.
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